However, Slot et al. observed that the risk of clinical progression in subjects carrying APOE ε4 is associated with elevated levels of ApoA-1 in CSF but reduced levels in plasma, suggesting the need to clarify the role of ApoA-1 in the development of AD [68]. The gene discussed is APOE; the disease is Alzheimer disease.